Welcome news for Johnson & Johnson’s Invokana, as FDA backtracks on boxed warning added to the diabetes drug label in 2017

An FDA review found that results from recent Invokana clinical data suggest that the risk of amputation is still present, but is lower than initially thought. Credit: Shutterstock.

  • Invokana warning